Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of ARGX-117 in adults with multifocal motor neuropathy stabilized on IVIg
NL-OMON54143Phase 2Recruiting
- Sponsor
- argenx
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of empasiprubart in multifocal motor neuropathy (MMN) (6 arms), sponsored by argenx. Primary endpoint: Safety outcomes. Started Dec 2022; status: recruiting.
02
Drugs
empasiprubart
03
Conditions
multifocal motor neuropathy (MMN)
Beyond the preview
Go deeper on NL-OMON54143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54143.